$3.44
+0.09 (+2.69%)
Open$3.41
Previous Close$3.35
Day High$3.48
Day Low$3.36
52W High$4.83
52W Low$2.43
Volume—
Avg Volume729.4K
Market Cap279.23M
P/E Ratio—
EPS$-1.24
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+726.2% upside
Current
$3.44
$3.44
Target
$28.42
$28.42
$21.41
$28.42 avg
$38.37
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 67.39M | 38.69M | 57.05M |
| Net Income | -152,000,683 | -510,081,137 | 9.29M |
| Profit Margin | -225.6% | -1,391.4% | 16.3% |
| EBITDA | -164,298,079 | -479,400,827 | 17.50M |
| Free Cash Flow | — | — | 7.43M |
| Rev Growth | — | -5.2% | +3.4% |
| Debt/Equity | 0.41 | 3.41 | 0.94 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |